Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models

Ciclopirox olamine (CPX) is an antifungal agent that has recently demonstrated promising anti-neoplastic activity against hematologic and solid tumors. Here, we evaluated CPX compared with gemcitabine alone as well as their combination in human pancreatic cancer cell lines; BxPC-3, Panc-1, and MIA PaCa-2 and in humanized xenograft mouse models. We also examined the preclinical pharmacodynamic activity of CPX. CPX caused a pronounced decrease in cell proliferation and clonogenic growth potential. These inhibitory effects were accompanied by induction of reactive oxygen species (ROS), which were strongly associated with reduced Bcl-xL and survivin levels and activation of a panel of caspases, especially caspase-3, and finally resulted in apoptotic death. CPX-induced apoptosis was associated with reduced pEGFR (Y1068) and pAkt (Ser473) protein levels. Additionally, decreased proliferation was observed in CPX-treated xenografts tumors, demonstrating unique tumor regression and a profound survival benefit. Finally, we showed that CPX significantly abrogated gemcitabine-induced ROS levels in pancreatic tissues. These pre-clinical results have verified the superior antitumor efficacy of CPX over gemcitabine alone, while their combination is even more effective, providing the rationale for further clinical testing of CPX plus gemcitabine in pancreatic cancer patients.

[1]  C. Jordan,et al.  Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. , 2013, Experimental hematology.

[2]  M. Schaller,et al.  Ciclopirox Olamine Treatment Affects the Expression Pattern of Candida albicans Genes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors , 2003, Antimicrobial Agents and Chemotherapy.

[3]  Monika Schäfer-Korting,et al.  Oxygen accessibility and iron levels are critical factors for the antifungal action of ciclopirox against Candida albicans. , 2005, The Journal of antimicrobial chemotherapy.

[4]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[5]  K. Ryan,et al.  Autophagy and cancer. , 2012, Cold Spring Harbor perspectives in biology.

[6]  D. Carson,et al.  Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model. , 2011, In vivo.

[7]  J. Furuse,et al.  Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data , 2017, British Journal of Cancer.

[8]  M. Minden,et al.  Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies , 2014, American journal of hematology.

[9]  Xiuzhen Han,et al.  The antitumor activity of the fungicide ciclopirox , 2010, International journal of cancer.

[10]  J. Wrana,et al.  Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers. , 2011, Cancer research.

[11]  J. Dick,et al.  Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. , 2009, Blood.

[12]  A. Schimmer,et al.  The repositioning of the anti‐fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy , 2011, Journal of clinical pharmacy and therapeutics.

[13]  Yongcheng Song,et al.  Toward Repurposing Ciclopirox as an Antibiotic against Drug-Resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae , 2013, PloS one.

[14]  K. Tsai,et al.  Inorganic mercury causes pancreatic beta-cell death via the oxidative stress-induced apoptotic and necrotic pathways. , 2010, Toxicology and applied pharmacology.

[15]  Hiroki Takahashi,et al.  Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells. , 2013, Biochimica et biophysica acta.

[16]  Autophagy: regulation and role in development. , 2013, Autophagy.

[17]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[18]  I. B. Borel Rinkes,et al.  Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT. , 2017, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[19]  William Pao,et al.  AACR Cancer Progress Report 2016 , 2016, Clinical Cancer Research.

[20]  M. Karamouzis,et al.  Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer. , 2017, Cancer letters.

[21]  D. Monti,et al.  Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. , 2010, Drugs.

[22]  Yan Luo,et al.  Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway , 2014, Oncotarget.

[23]  H. Eckert,et al.  [Pharmacokinetics and biotransformation of the antimycotic drug ciclopiroxolamine in animals and man after topical and systemic administration]. , 1981, Arzneimittel-Forschung.

[24]  D. Wazer,et al.  Adjuvant therapy for pancreatic cancer. , 2014, JOP : Journal of the pancreas.

[25]  W. Mitch,et al.  Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. , 2004, The Journal of clinical investigation.

[26]  ErbB/HER receptor family in breast cancer--the more we search the more we learn. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Rebecca SY Wong,et al.  Apoptosis in cancer: from pathogenesis to treatment , 2011, Journal of experimental & clinical cancer research : CR.

[28]  A. Papavassiliou,et al.  Molecular and Cellular Mechanisms of Disease Ciclopirox Enhances Pancreatic Islet Health by Modulating the Unfolded Protein Response in Diabetes , 2022 .

[29]  T. Lawrence,et al.  The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer , 2008, Clinical Cancer Research.

[30]  C. Lengerke,et al.  Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development , 2013, Journal of cellular and molecular medicine.

[31]  D. Carson,et al.  Targeting Wnt pathway in lymphoma and myeloma cells , 2009, British journal of haematology.

[32]  E. Giovannetti,et al.  Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective , 2016, Cancer Chemotherapy and Pharmacology.

[33]  B. Stockwell,et al.  The role of iron and reactive oxygen species in cell death. , 2014, Nature Chemical Biology.

[34]  E. Schütz,et al.  [Studies on the pharmacology and toxicology of ciclopiroxolamine (author's transl)]. , 1981, Arzneimittel-Forschung.

[35]  J. Shea,et al.  Phenotype and Genotype of Pancreatic Cancer Cell Lines , 2010, Pancreas.

[36]  C. Pilarsky,et al.  Simultaneous gene silencing of Bcl-2, XIAP and Survivin re-sensitizes pancreatic cancer cells towards apoptosis , 2010, BMC Cancer.

[37]  R. Abrams,et al.  Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial , 2013, The Lancet. Oncology.

[38]  H. Dihazi,et al.  Impact of the antiproliferative agent ciclopirox olamine treatment on stem cells proteome. , 2013, World journal of stem cells.

[39]  J. Sicklick,et al.  Image based detection and targeting of therapy resistance in pancreatic adenocarcinoma , 2016, Nature.

[40]  A. Papavassiliou,et al.  Modulation of Pancreatic Islets' Function and Survival During Aging Involves the Differential Regulation of Endoplasmic Reticulum Stress by p21 and CHOP. , 2017, Antioxidants & redox signaling.

[41]  G. Georg,et al.  A Preclinical Evaluation of Minnelide as a Therapeutic Agent Against Pancreatic Cancer , 2012, Science Translational Medicine.

[42]  Sami Mahrus,et al.  Activation of Specific Apoptotic Caspases with an Engineered Small-Molecule-Activated Protease , 2010, Cell.

[43]  Aditya K. Gupta,et al.  Ciclopirox nail lacquer solution 8% in the 21st century. , 2000, Journal of the American Academy of Dermatology.

[44]  M. Karamouzis,et al.  Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. , 2009, The Lancet. Oncology.

[45]  C. Der,et al.  KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment , 2016, Cancers.

[46]  Rachael M. Crist,et al.  Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer , 2016, Nature Reviews Clinical Oncology.